文传商讯

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome
2024-06-20 23:47:00

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of E
2024-06-20 23:46:58